Effects of CD44 siRNA on inhibition, survival, and apoptosis of breast cancer cell lines (MDA-MB-231 and 4T1)

被引:2
作者
Dehbokri, Shaho Ghahremani [1 ]
Noorolyai, Saeed [1 ]
Baghbani, Elham [1 ,2 ]
Moghaddamneshat, Nilofar [3 ]
Javaheri, Tohid [4 ]
Baradaran, Behzad [1 ]
机构
[1] Tabriz Univ Med Sci, Immunol Res Ctr, Daneshghah Ave, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Islamic Azad Univ, Fac Basic Sci, Dept Biol,Ctr Tehran Branch, East Tehran Branch, Tehran, Iran
[4] Islamic Azad Univ, Mashhad Branch, Young Res & Elites Club, Mashhad, Iran
关键词
CD44; siRNA; Breast cancer; MDA-MB-231; DOXORUBICIN; METASTASIS;
D O I
10.1007/s11033-024-09572-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundBreast cancer (BC) is one of the most common cancers in the world. Despite the many advances that have been made in treating patients, many patients are still resistant to treatment. CD44 is one of the surface glycoproteins of BC cells that plays an important role in the proliferation of these cells and inhibition of their apoptosis. Therefore, targeting it can be a treatment way for BC patients.MethodsIn this study, the effect of anti-CD44 siRNA on the proliferation, apoptosis, and migration rate of MDA-MB-231 and 4T1 cells was investigated. The techniques used in this study were MTT assay, RT-PCR, and flow cytometry.ResultsThe apoptosis and proliferation rates in CD44 siRNA-treated cells were higher and lower, respectively, compared to untreated cells. Also, cell migration was less in treated cells compared to untreated cells. CD44 siRNA also decreased the expression of CXCR4, c-myc, Vimentin, ROCK, and MMP-9.ConclusionFinally, CD44 targeting can be a good treatment option to make BC cells more sensitive to apoptosis.
引用
收藏
页数:8
相关论文
共 33 条
  • [1] Al-Othman N, 2019, Breast Dis. (Preprint), P1
  • [2] Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells
    An, Hyunsook
    Kim, Ji Young
    Oh, Eunhye
    Lee, Nahyun
    Cho, Youngkwan
    Seo, Jae Hong
    [J]. PLOS ONE, 2015, 10 (11):
  • [3] Breast tumor heterogeneity
    Campbell, Lauren L.
    Polyak, Kornelia
    [J]. CELL CYCLE, 2007, 6 (19) : 2332 - 2338
  • [4] Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066
    Cheng, Cong-Cong
    Shi, Li-Hong
    Wang, Xue-Jian
    Wang, Shu-Xiao
    Wan, Xiao-Qing
    Liu, Shu-Rong
    Wang, Yi-Fei
    Lu, Zhong
    Wang, Li-Hua
    Ding, Yi
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (01) : 339 - 348
  • [5] Diebolder P, 2020, J Nucl Med.:jnumed. 120.249557
  • [6] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Dikshit, Rajesh
    Eser, Sultan
    Mathers, Colin
    Rebelo, Marise
    Parkin, Donald Maxwell
    Forman, David
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) : E359 - E386
  • [7] High Myc expression and transcription activity underlies intratumoral heterogeneity in triple-negative breast cancer
    Gupta, Nidhi
    Jung, Karen
    Wu, Chengsheng
    Alshareef, Abdulraheem
    Alqahtani, Hind
    Damaraju, Sambasivarao
    Mackey, John R.
    Ghosh, Sunita
    Sabri, Siham
    Abdulkarim, Bassam S.
    Bigras, Gilbert
    Lai, Raymond
    [J]. ONCOTARGET, 2017, 8 (17) : 28101 - 28115
  • [8] Evaluation of Inflammasome Activation in Peripheral Blood Mononuclear Cells of Hemodialysis Treated Patients with Glomerulonephritis
    Hashemi, Atieh
    Bigdeli, Razieh
    Shahnazari, Masoumeh
    Oruji, Farshid
    Fattahi, Somayeh
    Panahnejad, Erfan
    Ghadri, Ayda
    Movahedi-Asl, Elmira
    Mahdavi-Ourtakand, Masoumeh
    Asgary, Vahid
    Baghbani-Arani, Fahimeh
    [J]. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2021, 20 (03): : 609 - 617
  • [9] Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrowendothelial cells
    Hill, A.
    McFarlane, S.
    Mulligan, K.
    Gillespie, H.
    Draffin, J. E.
    Trimble, A.
    Ouhtit, A.
    Johnston, P. G.
    Harkin, D. P.
    McCormick, D.
    Waugh, D. J. J.
    [J]. ONCOGENE, 2006, 25 (45) : 6079 - 6091
  • [10] Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities
    Isazadeh, Houman
    Oruji, Farshid
    Shabani, Shima
    Behroozi, Javad
    Nasiri, Hadi
    Isazadeh, Alireza
    Akbari, Morteza
    [J]. MOLECULAR BIOLOGY REPORTS, 2023, 50 (11) : 9529 - 9543